Novel JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis

Findings from the PERSIST-1 study of patients with myelofibrosis suggest that pacritinib is significantly more effective than best available therapy (BAT), which includes a range of off-label treatments. At 24 weeks of treatment, 19.1% of patients on the pacritinib arm experienced spleen shrinkage, compared to only 4.7% of patients on the BAT arm.

Presented by Ruben A. Mesa, MD, Mayo Clinic Cancer Center, Scottsdale, AZ, at ASCO 2015

Year of Production:
Running Time:
Color/Sound:

2015
06:30
Color/Sound

Comments are closed.